Market Closed -
Nasdaq
02:00:00 04/05/2024 am IST
5-day change
1st Jan Change
5.13
USD
-1.35%
+1.79%
-34.15%
Syros Pharmaceuticals : XBRL Q3 2020
November 06, 2020 at 04:55 am IST
Quarterly report pursuant to Section 13 or 15(d)
Document and Entity Information
Document and Entity Information - shares
9 Months Ended
Cover [Abstract]
Entity Registrant Name
SYROS PHARMACEUTICALS, INC.
Trading Symbol
SYRS
Entity Central Index Key
0001556263
Document Type
10-Q
Document Period End Date
Sep. 30, 2020
Amendment Flag
false
Current Fiscal Year End Date
--12-31
Entity Filer Category
Accelerated Filer
Entity Common Stock, Shares Outstanding
45,810,735
Document Fiscal Year Focus
2020
Document Fiscal Period Focus
Q3
Entity Small Business
true
Entity Ex Transition Period
true
Entity Emerging Growth Company
true
Entity Current Reporting Status
Yes
Entity Shell Company
false
Entity File Number
001-37813
Entity Tax Identification Number
45-3772460
Entity Address, Address Line One
35 CambridgePark Drive
Entity Address, Address Line Two
4th Floor
Entity Address, City or Town
Cambridge
Entity Address, State or Province
MA
Entity Address, Postal Zip Code
02140
City Area Code
617
Local Phone Number
744-1340
Document Quarterly Report
true
Document Transition Report
false
Entity Interactive Data Current
Yes
Entity Incorporation, State or Country Code
DE
Title of 12(b) Security
Common Stock, $0.001 par value
Security Exchange Name
NASDAQ
Attachments
Original document
Permalink
Disclaimer
Syros Pharmaceuticals Inc. published this content on 31 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 November 2020 23:24:06 UTC
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
10/04
MT
Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise
09/04
MT
Syros Gets FDA Fast-Track Designation for Tamibarotene
09/04
DJ
Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
09/04
CI
Health Care Rises as Upward Momentum Builds -- Health Care Roundup
29/03
DJ
Health Care Jumps as Upward Momentum Builds -- Health Care Roundup
28/03
DJ
Transcript : Syros Pharmaceuticals, Inc., 2023 Earnings Call, Mar 27, 2024
27/03
Earnings Flash (SYRS) SYROS PHARMACEUTICALS Reports Q4 Revenue $387,000
27/03
MT
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
27/03
CI
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
27/03
CI
North American Morning Briefing : Stocks Edge -2-
27/03
DJ
Syros Pharmaceuticals Completes Enrollment of 190 People in Phase 3 Trial of Tamibarotene
25/03
MT
Syros Pharmaceuticals Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in Select-MDS-1 Phase 3 Trial
25/03
CI
Sector Update: Health Care Stocks Mixed Late Afternoon
07/12
MT
Sector Update: Health Care
07/12
MT
Top Midday Gainers
07/12
MT
Transcript : Syros Pharmaceuticals, Inc. - Special Call
06/12
Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
06/12
CI
Top Premarket Decliners
27/11
MT
Transcript : Syros Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 14, 2023
14/11
Earnings Flash (SYRS) SYROS PHARMACEUTICALS Reports Q3 Revenue $3.8M, vs. Street Est of $3.9M
14/11
MT
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
14/11
CI
Top Premarket Gainers
17/23/17
MT
Sector Update: Health Care Stocks Lower Late Afternoon
03/23/03
MT
Sector Update: Health Care Stocks Retreating Monday Afternoon
02/23/02
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
More about the company
Last Close Price
5.13
USD
Average target price
19.25
USD
Spread / Average Target
+275.24%
Consensus
1st Jan change
Capi.
-34.15% 137M +25.69% 47.9B +46.90% 41.42B -3.46% 40.7B -6.20% 28.92B +9.17% 25.55B -20.42% 19.27B +0.17% 12.15B +28.07% 12.14B -1.24% 11.99B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1